| Click for the Finfacts Ireland Portal Homepage |

Finfacts Business News Centre

Home 
 
 News
 Irish
 Irish Economy
 EU Economy
 US Economy
 UK Economy
 Global Economy
 International
 Property
 Innovation
 
 Analysis/Comment
 
 Asia Economy

RSS FEED


How to use our RSS feed

Follow Finfacts on Twitter

 
Web Finfacts

See Search Box lower down this column for searches of Finfacts news pages. Where there may be the odd special character missing from an older page, it's a problem that developed when Interactive Tools upgraded to a new content management system.

Welcome

Finfacts is Ireland's leading business information site and you are in its business news section.

Links

Finfacts Homepage

Irish Share Prices

Euribor Daily Rates

Irish Economy

Global Income Per Capita

Global Cost of Living

Irish Tax - Income/Corporate

Global News

Bloomberg News

CNN Money

Cnet Tech News

Newspapers

Irish Independent

Irish Times

Irish Examiner

New York Times

Financial Times

Technology News

 

Feedback

 

Content Management by interactivetools.com.

News : Irish Last Updated: Feb 8, 2011 - 8:54 AM


Elan reports annual operating profits in 2010 for first time since 2001; Annual net loss increased from $176.2m to $324.7m
By Finfacts Team
Feb 8, 2011 - 8:44 AM

Email this article
 Printer friendly page

Elan, the Irish drugs company, today reported annual operating profits in 2010, before other charges and gains, for the first time since 2001. The annual net loss increased from $176.2m to $324.7m.

Revenues for the 12 months to the end of December rose by 5% to $1.2bn, headed by an 18% increase in revenues from its multiple sclerosis (MS) drug Tysabri.

CFO Shane Cooke said the revenue increase combined with a 9% decrease in operating expenses, before other charges and gains, led to a significant improvement of 73% in Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) to $166.5m.

As a result Elan recorded operating profits, before other charges and gains, for the first time since 2001. Total debt fell by 17% and Cooke said although the results reflect an improved operating performance, the net loss for the year increased from $176.2m to $324.7m.

The loss mainly related to a settlement agreement on dubious selling practices Elan reached with the US government regarding Zonegran for which it recorded a charge of $206.3m and the inclusion of a net gain in 2009 of $108.7m  associated with a deal with Johnson & Johnson.

Sales of the MS drug rose to $851.5m for the full year from $724.3m in 2009. The number of patients using the drug worldwide increased by 17% to about 56,000.

Results detail

Davy's Jack Gorman commented: "Elan ended the year positively with Q4 revenue growth of 3% to $308.9m; adjusted EBITDA of $45.9m that compared reasonably well with tough comps; and a modest loss per share of -1c on an adjusted basis.

Compared to guidance, the Q4 and FY out-turn was better than expectations – adjusted EBITDA of $166.5m compared to guidance of approximately $150m. It was also modestly ahead of our own forecast of $165m.

The main features of Q4 were:

Revenue growth of 3% was delivered by Tysabri and Ampyra. In aggregate, these grew by 25% year-on-year (yoy) and offset the elimination of Maxipime and Azactam and the genericisation of Skelaxin.

Operating costs were broadly as expected, +12% yoy and all driven by R&D spending.

Gross cash and equivalents totalled $657m ($453.3m excluding the Zonegran settlement). This compares to guidance of approximately $400m and our own forecast of $436m.

For 2011 guidance, Elan has outlined that revenue growth will accelerate beyond the 2010 rate of 5% (Davy: +12%); adjusted EBITDA of approximately $200m (Davy: $225m); operating costs of $470-500m (Davy: $534m). Elan also expects to be cash flow positive this year (we have a net cash inflow of $56m).

More colour on guidance and R&D updates is likely to be provided on the conference call at 13.30 GMT: +1 303 223 0114 [outside US]; 800 747 9564 [in US].

Davy View: These are strong numbers from Elan and highlight Tysabri's operational leverage in the P&L and cash flow model. This leverage will become even more apparent in 2011. We will review our own forecasts in light of guidance, but our first instinct is that we are comfortable to remain somewhat above base guidance."

Related Articles
Related Articles


© Copyright 2011 by Finfacts.com

Top of Page

Irish
Latest Headlines
Ryanair revises up full-year profit guidance
AIB bank profitable in third quarter
Ryanair announces half-year profits up 32% to €795m
Ryanair benefits from improved customer service
Ryanair to buy 100 new Boeing 737 MAX 200
Finfacts server migration Thursday
State-owned Allied Irish Banks reports H1 2014 profit as bad loan charges plunge
Ryanair reports profit in its financial first quarter soared 152%
UK firm opens van dealership in Dublin
Ryanair reports 8% fall in full-year profit; US services to commence in 2019
Global Financial Centres Index: New York overtakes London; Dublin slips to 66 of 83 cities
Bank of Ireland reports “significant” improvement in 2013 results
Sale process of IBRC UK projects Rock and Salt completed
CRH says 2014 will be year of profit growth after reporting 2013 loss
Ryanair reports third-quarter loss
Irish Water says it saved €100m in setup costs
RSA Insurance fires two Irish executives for large loss/ accounting irregularities
Bank of Ireland will have to raise provisions by €1.4bn; AIB says it's "well capitalised"
CRH reports slightly improved third quarter
Central Bank says ownership of Newbridge Credit Union transferred to permanent tsb
Ryanair reports H1 profits rose by 1% to €602m
Dublin Web Summit: Irish Stock Exchange and NASDAQ OMX announce dual listing plan
Irish pension managed funds returned to growth during September
Dan O’Brien resigns as economics editor of The Irish Times
Central Bank says no action required on Anglo tapes revelations
Ryanair flew 9m passengers and Aer Lingus carried 1.1m in August
UK Competition Commission says Ryanair must cut Aer Lingus stake to 5%
CRH reports H1 2013 revenue dip and loss
Vodafone refunded UK after discovery of Irish tax haven deal
RBS reports half year profit; Ulster Bank posts reduced loss
Bank of Ireland cuts pretax losses in HI 2013 to €504m
Irish State-owned Allied Irish Banks reports losses of €758m in H1 2013
Service Announcement
Irish managed pension funds declined in June
VHI reports 2012 surplus of €54.3m; Health insurance made loss
Ex- Elan director says management / board "not competent to run a business"
Aer Lingus to put €140m in employees pensions fund; Ryanair apoplectic
Wednesday Newspaper Review - Irish Business News and International Stories - - May 22, 2013
Tuesday Newspaper Review - Irish Business News and International Stories - - May 21, 2013
Ryanair, Europe’s biggest low cost carrier, announced Monday record annual profits of €569m - - up 13%